Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
86
days
Vaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
Authors
Nancy Dezutter; Katherine Theiss-Nyland; Marie-Pierre David; Quentin Deraedt; Christian Felter; Maria João Fonseca; Susan I. Gerber; Emily K. Horn; Veronica Hulstrøm; Philip Joosten; Jean-Yves Pirçon; Bruno Salaun; Pei-Yong Shi; Marie Van der Wielen; Natalie Vassilouthis; Lucile Warter; Lisa White; Dominique Descamps; Susie Barnes; Sanjay GurunathanShow moreShow less
Affiliations
1. GSKShow moreShow less
163
days
Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials
Authors
Kangning Wang; Jialei Hu; Huagen Chen; Zhu Wang; Xianchao Zhu; Hongxing PanShow moreShow less
Affiliations
1. School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, China; 2. Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, China; 3. Jiangsu Provincial Medical Innovation Center, National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, China; 4. Shanghai Reinovax Biologics Co., Ltd., and Changchun Reinovax Biologics Co., Ltd., Shanghai, ChinaShow moreShow less
75
days
The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis
Authors
Matthew Napier; Angus Macfarlane; Ellie Tunnicliffe; Simon Brassel; Camilla Cahill; Sally Ryan; Christoph Lohan; Valda Struwig; Jeffrey Vietri; Diana Mendes; Tianyan Hu; Lotte SteutenShow moreShow less
Affiliations
1. Office of Health Economics; 2. Pfizer Australia Pty; 3. PfizerShow moreShow less
51
days
Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responses
Authors
Zihan Zhang; Huiwen Zheng; Longding LiuShow moreShow less
Affiliations
1. Chinese Academy of Medical Sciences and Peking Union Medical College; 2. Chinese Academy of Medical SciencesShow moreShow less
40
days
Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany
Authors
Muloongo Simuzingili; Peter P. Mueller; Lisa M. Oexle; Marion de Lepper; Zinan Yi; Kwame Owusu-EduseiShow moreShow less
Affiliations
1. Merck &; 2. MSD Sharp & Dohme GmbHShow moreShow less
238
days
Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary
Authors
Laura Wagner; Marc Messier; James H. Stark; Erik LamberthShow moreShow less
Affiliations
1. aValneva Austria GmbH, Vienna, Austria; 2. bGlobal Vaccines and Anti-infectives Medical and Scientific Affairs, Pfizer Inc, Cambridge, MA, USA; 3. cVaccine Research and Development, Pfizer Inc, Collegeville, PA, USAShow moreShow less
FAQ
How long does Expert Review of Vaccines take to review a manuscript?
As of 2026-11-19, CrushSCI has 21 complete review records for Expert Review of Vaccines. The fastest paper went from submission to acceptance in 25 days (Rational design of M2e-based nanoparticle vaccines for universal influenza a protection, received 2026-07-17, accepted 2026-08-11); the slowest took 322 days. The average is 143.2 days and the median is 123 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
